Hanoi, 15 July 2024 - Bayer Vietnam, the Hanoi Stroke Association (HNSA), and the University of Oxford announce a new collaboration to enhance stroke management and the quality of scientific research in Vietnam. The MOU signing ceremony, held at the Stroke Center, Bach Mai Hospital, witnessed by leaders from all partner organizations, marks a significant milestone in the collaborative efforts to improve patient care and outcomes.

Recognizing the critical role of continuous research and analysis of scientific data in the treatment of atrial fibrillation and stroke, the three parties are committed to the common goal of advancing the research capacity and fostering the development and publication of clinical data within medical community in Vietnam. By addressing data gaps, this collective effort supports improved clinical decision-making and patient care optimization.

Under the MOU, a comprehensive program titled "Improving the Quality of Scientific Research and Stroke Management, period 2024-2025" will be developed, encompassing various key areas of scientific research and publication activities. Specific program will be further discussed and agreed upon by the parties, considering the criteria and capacity of each organization.

Furthermore, the partnership seeks to establish and nurture professional collaboration with international organizations to elevate the quality of stroke research in Vietnam. By combining local expertise and data with technical guidance from counterparts at leading medical institutions overseas, multi-national projects are expected to generate more robust insights applicable worldwide, strengthening the global contribution of Vietnamese stroke specialists while expediting adoption of evidence-based best practices in the country.

According to Mr. Ingo Brandenburg, Managing Director of Bayer Vietnam, the company will actively collaborate with medical experts in the development of training programs for healthcare professionals and the community. Leveraging its scientific expertise, Bayer will provide input to enhance the quality of training and education programs, facilitate knowledge updates, further contributing to the overall objectives of the partnership, in consultation with the Hanoi Stroke Association, Oxford University, and respective experts involved.

"This solidarity between leading organizations represents a significant step for stroke care and research in Vietnam. By combining strengths, we hope to empower health professionals and tangibly enhance patient well-being. This is aligned with our vision of Health for all." Mr. Ingo Brandenburg emphasized at the ceremony that.

Dr. Tran Cong Minh, Researcher at University of Oxford shared, “Today’s ceremony represents a collaborative effort on enhancing scientific research and stroke management. Partnering with Hanoi Stroke Association and Bayer Viet Nam has assured our commitment towards improving treatment quality, through developing research, training medical programs and is updated with latest clinical data.”

With a sustained, multi-pronged approach over the coming years, this alliance is well-positioned to make a truly meaningful and lasting impact - elevating standards of treatment, research and patient outcomes to international levels. Ultimately, through these collective efforts, more Vietnamese families will gain access to quality stroke management that improves lives.

About Hanoi Stroke Association
Hanoi Stroke Association is a socio-professional organization of Vietnamese citizens based in Hanoi, but our impact is nation-wide. The Association operates with the mission of improving professional qualifications, standardizing techniques in the fields of research, training, diagnostics, and treatment of stroke and related fields.

About the University of Oxford
The University of Oxford was ranked first in the Times Higher Education and second amongst global universities from QS World University Rankings. The foundation of this success is based on innovative, ground-breaking scientific achievements.

The University of Oxford is famous for their excellence in scientific research and is home to many outstanding, talented individuals across the globe. We continuously strive for enhancing life to millions of people, solving important problems that the world is facing thanks to our wide partner network. Our scale and multi-area researches allow us to bring new ideas, innovations with unique solutions.

Through our research facility – Oxford University Innovation, Oxford is the leading university in the United Kingdom with the amount of applications for patents as well as the number of associated commercial companies, reaching 200 established companies since 1988. Over one-third of these businesses was created in the past 3 years. The university plays a big role in bringing prosperity to Oxfordshire County and the United Kingdom, contributing 15,7 billion pounds to the British economy in 2018/19 and created over 28.000 full-time jobs.

The Nuffield Department of Clinical Neurosciences has developed a long-standing research and training program that is known for its great reputation both locally and internationally. The department consists of 5 divisions: Wolfson Centre for Prevention of Stroke and Dementia, Division of Clinical Neurology, Nuffield Division of Anaesthetics, Nuffield Laboratory of Ophthalmology and Wellcome Centre For Integrative Neuroimaging. Located at John Radcliffe Hospital, The Nuffield Department of Clinical Neurosciences has curated a comprehensive environment where research activities, education, training and clinical care are closely connected. This allows the facility to develop new approaches and methods in finding, diagnosing and treatment in brain diseases.

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2023, the Group employed around 100,000 people and had sales of 47.6 billion euros. R&D expenses before special items amounted to 5.8 billion euros. For more information, go to www.bayer.com

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.